ALNYLAM PHARMACEUTICALS, INC. (ALNY) Return on Tangible Equity

ALNYLAM PHARMACEUTICALS, INC. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

• ALNYLAM PHARMACEUTICALS, INC. return tang equity for the quarter ending 2026-06-30 was 54.15%, a change of 105.62% year-over-year.
• ALNYLAM PHARMACEUTICALS, INC. return tang equity for the quarter ending 2026-03-31 was 46.17%, a change of 100.27% year-over-year.
• ALNYLAM PHARMACEUTICALS, INC. return tang equity for the quarter ending 2025-12-31 was 34.49%, a change of 450.00% year-over-year.
• ALNYLAM PHARMACEUTICALS, INC. return tang equity for the quarter ending 2025-09-30 was 32.87%, a change of 1064.46% year-over-year.
• ALNYLAM PHARMACEUTICALS, INC. return tang equity for fiscal 2025 was 39.77%, a change of 456.09% from fiscal 2024.
• ALNYLAM PHARMACEUTICALS, INC. return tang equity for fiscal 2024 was -416.32%, a 308.92% decline from fiscal 2023.
• ALNYLAM PHARMACEUTICALS, INC. return tang equity for fiscal 2023 was 199.28%, a 72.08% decline from fiscal 2022.
• ALNYLAM PHARMACEUTICALS, INC. return tang equity for fiscal 2022 was 713.67%, a change of 858.73% from fiscal 2021.